

# Nomination Committee for the CellaVision Annual General Meeting 2025

Ahead of the Annual General Meeting 2025, the Nomination Committee consists of:

- Christer Fåhraeus, Christer Fåhraeus with Companies
- Nicklas Hansen, William Demant Invest A/S
- Anette Andersson, SEB Investment funds
- Emil Hjalmarsson, Grenlunden CEVI AB

Emil Hjalmarsson has been appointed Chairman of the Nomination Committee.

The Nomination Committee shall prepare proposals for the Annual General Meeting in 2025 regarding the election of Chairman of the General Meeting, members of the Board of Directors, Chairman of the Board, auditor, fees for the members of the Board including division between the Chairman, and the other Board members as well as fees for committee work and fees to the company's auditor.

The CellaVision Annual General Meeting in 2025 will be held in Lund at 15:00 o'clock CEST, on May 6, 2025.

Shareholders wishing to have matters considered at the Annual General Meeting can send a written request by email to: [bolagsstamma@cellavision.se](mailto:bolagsstamma@cellavision.se), or ordinary mail addressed to: The Board of Directors, CellaVision AB, Mobilvägen 12, 223 62 Lund. The request must have been received at the latest seven weeks before the Annual General Meeting in order to be included in the notice to attend and thus the agenda of the Annual General Meeting.

## Contact

---

Adele Horn  
Corporate Communications & Investor Relations Manager  
Tel: + 46 46 460 26 04  
[www.cellavision.com](http://www.cellavision.com)  
[adele.horn@cellavision.com](mailto:adele.horn@cellavision.com)

## About Us

---

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 12 local market support organizations covering more than 40 countries. In 2023, sales were SEK 677 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at [www.cellavision.com](http://www.cellavision.com)

## Attachments

---

[Nomination Committee for the CellaVision Annual General Meeting 2025](#)